Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Takao MorinagaTakashi InozumeMasahito KawazuYouki UedaNicolas SaxKazuo YamashitaShusuke KawashimaJoji NagasakiToshihide UenoJason LinYuuki OharaTakeshi KuwataHiroki YukamiAkihito KawazoeKohei ShitaraAkiko Honobe-TabuchiTakehiro OhnumaTatsuyoshi KawamuraYoshiyasu UmedaYu KawaharaYasuhiro NakamuraYukiko KiniwaAyako MoritaEiki IchiharaKatsuyuki KiuraTomohiro EnokidaMakato TaharaYoshinori HasegawaHiroyuki ManoYutaka SuzukiHiroyoshi NishikawaYosuke TogashiPublished in: Cancer research communications (2022)
Several patients experience mixed responses to immunotherapies, but the biological mechanisms and clinical significance remain unclear. Our results from clinical and mouse studies underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.